scholarly journals Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study

2020 ◽  
pp. 1-16 ◽  
Author(s):  
Maryam Enayatkhani ◽  
Mehdi Hasaniazad ◽  
Sobhan Faezi ◽  
Hamed Gouklani ◽  
Parivash Davoodian ◽  
...  
Keyword(s):  
In Silico ◽  
Vaccine Candidate ◽  
Reverse Vaccinology ◽  
Epitope Vaccine ◽  
In Silico Study

scholarly journals Design of multi-epitope vaccine candidate against SARS-CoV-2: a in-silico study

2020 ◽  
pp. 1-9 ◽  
Author(s):  
K. Abraham Peele ◽  
T. Srihansa ◽  
S. Krupanidhi ◽  
Vijaya Sai Ayyagari ◽  
T. C. Venkateswarulu
Keyword(s):  
In Silico ◽  
Vaccine Candidate ◽  
Epitope Vaccine ◽  
In Silico Study

scholarly journals In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection

2020 ◽  
Vol 16 (3) ◽  
pp. e1008243 ◽  
Author(s):  
Ayat Zawawi ◽  
Ruth Forman ◽  
Hannah Smith ◽  
Iris Mair ◽  
Murtala Jibril ◽  
...  
Keyword(s):  
T Cell ◽  
In Silico ◽  
Helminth Infection ◽  
Vaccine Candidate ◽  
Cell Epitope ◽  
T Cell Epitope ◽  
Epitope Vaccine ◽  
Parasitic Helminth ◽  
In Silico Design

scholarly journals In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Robert Adamu Shey ◽  
Stephen Mbigha Ghogomu ◽  
Kevin Kum Esoh ◽  
Neba Derrick Nebangwa ◽  
Cabirou Mounchili Shintouo ◽  
...  
Keyword(s):  
In Silico ◽  
Vaccine Candidate ◽  
Epitope Vaccine ◽  
In Silico Design

Designing an epitope vaccine against Dermatophagoides pteronyssinus: An in silico study

Acta Tropica ◽  
2021 ◽  
pp. 106028
Author(s):  
Aryani Adji ◽  
Nurdjannah J. Niode ◽  
Ventje V. Memah ◽  
Jimmy Posangi ◽  
Greta J.P. Wahongan ◽  
...  
Keyword(s):  
In Silico ◽  
Dermatophagoides Pteronyssinus ◽  
Epitope Vaccine ◽  
In Silico Study

scholarly journals Exploring SARS-COV-2 Structural Proteins to Design a Multi-Epitope Vaccine Using Immunoinformatics Approach: an In Silico Study

2021 ◽  
pp. 104390
Author(s):  
Samira Sanami ◽  
Morteza Alizadeh ◽  
Masoud Nosrati ◽  
Korosh Ashrafi Dehkordi ◽  
Fatemeh Azadegan-Dehkordi ◽  
...  
Keyword(s):  
In Silico ◽  
Structural Proteins ◽  
Epitope Vaccine ◽  
In Silico Study

Immunoinformatics approaches to design: A novel multi-epitope vaccine candidate against SARS-CoV-2 and it’s in silico expression (Preprint)

2021 ◽  
Author(s):  
Ravi Deval ◽  
Ayushi Saxena ◽  
Zeba Mueed ◽  
Dibyabhaba Pradhan ◽  
Pankaj Kumar Rai
Keyword(s):  
B Cell ◽  
In Silico ◽  
Vaccine Candidate ◽  
Rna Virus ◽  
Consensus Sequence ◽  
Structure Model ◽  
Epitope Vaccine ◽  
B Cell Epitopes ◽  
Epitope Vaccines ◽  
Further Development

BACKGROUND SARS-CoV-2, belonging to the Coronaviridae family, is a novel RNA virus, known for causing fatal disease in humans called COVID-19. Researchers all around the world are keen on developing a precise treatment or vaccine against this deadly disease. OBJECTIVE The main objective of this paper is to design a novel multi-epitope vaccine candidate against SARS-CoV-2 using immunoinformatics tools. METHODS A consensus sequence was generated from various genomes of SARS-Cov-2 available from various countries of the outbreak at the ViPR database using JalView software. T cell and B cell epitopes were predicted by restricting them to certain HLA alleles using various servers (nHLApred, NetMHCIIpan v.3.1, ABCpred) and were validated using IEDB tools. Using these epitopes and adjuvant, a multi-epitope vaccine was constructed in-silicoand was later subjected to allergenicity, antigenicity and physicochemical properties profiling along with identification of conformational B-cell epitopes. The designed vaccine was evaluated via codon optimization by the Jcat server and finally, it’s in-silicoexpression was done in pET-28a(+) vector using snap-gene software. RESULTS A total of 18 epitopes (both T and B cell) were predicted that constituted vaccine construct along with adjuvant and end tag. Vaccine construct was validated and its best structure model was successfully docked with human Toll-like receptors. In-silico expression of the designed vector was also seen in pET-28a(+) plasmid. CONCLUSIONS The designed novel vaccine candidate has been validated in-silico to elicit robust immune responses hence; it can be used as a potential model for further development of multi-epitope vaccines in the laboratory.

Sign in / Sign up

Export Citation Format

Share Document